Research peptide blend · Fact sheet
Tesamorelin + CJC + ipamorelin
Also known as Tesa/CJC/IPA blend
Tesamorelin + CJC + ipamorelin combines tesamorelin, a CJC-labeled GHRH analog and ipamorelin. Human evidence for the exact blend is not established; studies of individual ingredients do not validate the mixture.
What is Tesamorelin + CJC + ipamorelin?
tesamorelin, a CJC-labeled GHRH analog and ipamorelin are discussed together under this name. Ratios, salts and formulations can differ between products.
The CJC ingredient must be specified as DAC or no-DAC before comparing exposure. The blend name alone does not establish that identity.
Benefits & claims
Interest centers on growth-hormone release and body composition.
What the evidence supports
- Tesamorelin and CJC-related molecules address the GHRH pathway; more ingredients do not establish a better clinical response.
- The available ingredient trials do not evaluate this three-agent mixture.
- A named ingredient and total blend amount cannot establish each component dose or a valid schedule.
Research areas
- Interest centers on growth-hormone release and body composition.
Dosage & frequency
No established human regimenThe reviewed sources do not establish a human treatment amount or frequency for Tesamorelin + CJC + ipamorelin. Animal and laboratory exposures are not human regimens.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
Formulation differences
- The CJC ingredient must be specified as DAC or no-DAC before comparing exposure. The blend name alone does not establish that identity.
- No published ingredient regimen can be assembled into a supported regimen for this combination.
Interactions & precautions
- The reviewed sources do not establish a comprehensive human interaction profile for this exact substance or combination.
What is still unresolved
- Human efficacy and adverse-event rates for the exact formulation
- Chemical compatibility, stability and ingredient identity
- Whether combined effects differ from the ingredients alone
Side effects & risks
- Tesamorelin label warnings remain relevant context, but do not supply a complete mixture safety profile.
- Additional growth-hormone stimulation may change metabolic exposure; the size and clinical consequences are unknown.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Limited or unclear evidenceThe reviewed sources do not establish efficacy or a human regimen for this exact combination. Ingredient-only experiments cannot show that the mixture is effective, synergistic or safer.
Studies
Albumin-binding single agent, not a three-component blend.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
No attributable personal accounts were found in the sources reviewed.
Approval status
There is no FDA-approved Tesamorelin + CJC + ipamorelin product or established approved use for this combination. Ingredient approvals, where present, do not transfer to the blend.
No FDA-approved product for this entry
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Human efficacy and adverse-event rates for the exact formulation
- Chemical compatibility, stability and ingredient identity
- Whether combined effects differ from the ingredients alone
Summary
A named ingredient and total blend amount cannot establish each component dose or a valid schedule.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- fdaFDA prescribing information: Egrifta SV
Official label describing indication, limitations, and safety information.
- pubmedCJC-1295 human hormone-response trial
Albumin-binding single agent, not a three-component blend.
- fdaFDA: safety concerns for nominated bulk substances
Ingredient-specific uncertainties; compounding consideration is separate from FDA drug approval.